Hemodez-H (Haemodes-N)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substancePotassium Chloride + Calcium Chloride + Magnesium Chloride + Sodium Hydrocarbonate + Sodium Chloride + Povidone-8 Thousand.Potassium Chloride + Calcium Chloride + Magnesium Chloride + Sodium Hydrocarbonate + Sodium Chloride + Povidone-8thousand
Similar drugsTo uncover
  • Hemodez-8000
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Hemodez-H
    solution d / infusion 
    MAKSFARM, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    MOSFARM, LLC    
  • Hemodez-H
    solution d / infusion 
    ESKOM NPK, OAO     Russia
  • Hemodez-H
    solution d / infusion 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    Kursk Biofactory - BIOK, FKP     Russia
  • Hemodez-H
    solution d / infusion 
    RESTER, CJSC     Russia
  • Hemodez-H
    solution d / infusion 
    ELFARMI, LTD.     Russia
  • Hemodez-H
    solution d / infusion 
    PHARMSTANDART-UFIM VITAMIN FACTORY, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    DALHIMFARM, OJSC     Russia
  • Hemodez-H
    solution d / infusion 
    ATOLL, LLC     Russia
  • Krasgemodez 8000
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Krasgemodez 8000
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Neohemodes
    solution in / in 
    SYNTHESIS, OJSC     Russia
  • Neohemodes
    solution inwards 
    FIRM MEDPOLIMER, JSC     Russia
    • Dosage form: & nbspsolution for infusions
    Composition:

    Active substances:

    Povidone-8000 - 60,0 g

    Sodium chloride - 5,50 g

    Potassium chloride - 0,42 g

    Calcium chloride hexahydrate in terms of 100% - 0.50 g

    Magnesium chloride hexahydrate in terms of 100% -0.005 g

    Sodium bicarbonate - 0.23 g

    Excipient:

    water for injections - up to 1 l

    Description:Transparent liquid from light yellow to yellow.
    Pharmacotherapeutic group:Detoxifying agent
    ATX: & nbsp

    B.05.A.A   Blood plasma preparations and plasma-substituting drugs

    Pharmacodynamics:
    The action of Hemodeza-H is due to the ability of low molecular weight povidone to bind toxins circulating in the blood and quickly remove them from the body. The most fully binds toxins circulating in the blood of patients with shigellosis, salmonellosis, food intoxication. The complex of electrolytes (sodium, potassium, calcium, magnesium, bicarbonate) that is part of the preparation ensures preservation of the acid-alkaline balance of blood.

    The drug contributes to the elimination of stasis of erythrocytes in capillaries, developing with intoxication of any origin, which leads to an improvement in microcirculation. It enhances kidney blood flow, increases glomerular filtration and increases diuresis. The drug is non-toxic, does not have pyrogenic properties.

    Pharmacokinetics:

    Povidone does not undergo metabolic changes in the body. Quickly excreted by the kidneys, within 4 hours 80 %, and after 12-24 hours - completely.

    Ions of potassium, sodium, magnesium, calcium are not kept for long in the vascular bed, quickly distributed across all tissues; are excreted in the urine, in small amounts - with feces, then, with tears.

    Indications:

    Shock (post-traumatic, postoperative, burn, hemorrhagic), intoxication(toxic diseases of the gastrointestinal tract: dysentery, dyspepsia, salmonellosis; as a means of detoxification in the postoperative period with peritonitah; burn, radiation and hemolytic disease; intestinal obstruction; thyreatoxicosis; liver disease, accompanied by the development of hepatic failurethirds; sepsis; pneumonia; acute phase of myocardial infarction), toxemia of newborns.

    Contraindications:

    Hypersensitivity to the components of the drug, intracranial hypertension, hemorrhagic stroke, condition after craniocerebral trauma, chronic cardiac failuresufficiency of II-IV functional class for NYHA, respiratory insufficiency, severe allergic reactions, thromboembolism, oliguria, anuria, acute nephritis, bronchial asthma, phlebothrombosis.

    Carefully:Not described.
    Pregnancy and lactation:During pregnancy, the drug is used if the benefit to the mother exceeds the possible risk to the fetus. During the use of the drug, breastfeeding should be discontinued.
    Dosing and Administration:
    Intravenously drip (40-80 cap / min).

    The dose depends on the age of the patient and the severity of intoxication. In case of shock and intoxication of any origin, a single dose for adults and children over 15 years of age is 200-500 ml.

    For children under 15 years - 2.5 ml / kg. The maximum single dose for children under 2 years is 70 ml, for children from 2 to 5 years - 100 ml, for children from 6 to 9 years - 150 ml, for children from 10 to 15 years - 200 ml. The drug is administered once or twice within 1-10 days, depending on the severity of intoxication. When thyrotoxicosis is administered intravenously, 20-40 cap / min - the maximum single dose for adults is 400 ml. When hepatitis and cirrhosis, accompanied by the development of hepatic insufficiency, injected at a dose of 400 ml for 5-7 days.

    In acute gastrointestinal infections, burn and radiation diseases are administered 1-2 times a day; with hemolytic disease and toxemia of newborns - 2-8 times a day (daily or every other day); with large focal myocardial infarction (in 1 day) - 200 ml once,In case of complications (prolonged pain syndrome, severe arrhythmias, cardiogenic shock or a combination of these complications with concomitant diabetes), the drug is given again on the 2nd day at a dose of 200 ml.

    Side effects:

    Reduced blood pressure, tachycardia, difficulty breathing (with rapid administration), allergic reactions of varying severity (up to the development of anaphylactic shock). Infection at the injection site, thrombosis or phlebitis, spreading from the site of infusion.

    Overdose:In case of an overdose, the drug should be withdrawn and symptomatic therapy should be performed.
    Interaction:

    When mixed with solutions containing a phosphate ion and carbonation, a precipitate may precipitate.

    Special instructions:

    With extensive burns combined with the introduction of plasma, albumin, gamma globulin.

    Before the start of the infusion, it is necessary to check the shelf life of the drug. The drug should be clear, free of sediment, sediment and mold. The results of visual inspection are recorded in the medical history.

    In the process of treatment, it is necessary to monitor blood pressure and the patient's condition. Before administration, the solution is warmed to body temperature.

    Effect on the ability to drive transp. cf. and fur:

    Data on the effect of the drug on the ability to drive vehicles, mechanisms are absent.

    Form release / dosage:

    Solution for infusion.

    Packaging:For 200 ml and 400 ml in bottles of glass for blood, transfusion and infusion preparations. A bottle with instructions for use is placed in a pack of cardboard.

    28 bottles of 200 ml or 15 bottles of 400 ml, together with an equal number of instructions for use, are placed in boxes of corrugated cardboard with gaskets, with baffles or lattices ("nests") (for hospitals).

    Storage conditions:

    Store at a temperature of 2 to 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years. Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LS-001416
    Date of registration:01.11.2011 / 15.05.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:DALHIMFARM, OJSC DALHIMFARM, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp21.03.2017
    Illustrated instructions
      Instructions
      Up